Abstract 84P
Background
Macrophages represent the main infiltrating immune subset in most cancer types and tumor-associated macrophages (TAMs) sustain tumor growth, promote invasion and mediate immune suppression. Interestingly, a population of lipid-loaded macrophages has been recently identified in prostate cancer, colon cancer and melanoma. However, the mechanisms that drive lipid accumulation in macrophages and the functional impact of lipid-loading still need to be uncovered.
Methods
We profiled the cancer immune infiltrate in a murine model of melanoma and we performed bulk RNA sequencing of lipid-loaded macrophages to investigate pathways involved in lipid accumulation. We applied in vitro assays to dissect the interplay between macrophages and melanoma cells and we took advantage of immunofluorescence analysis to study the mechanisms responsible for lipid accumulation in tumor-conditioned macrophages.
Results
We confirmed that lipid accumulation is a feature of TAMs in melanoma and we observed that lipid-loaded macrophages express markers of immunosuppression, including arginase and PD-L1. Importantly, the abundance of lipid-loaded macrophages correlates with tumor size, suggesting their support to tumor progression. In vitro, cancer cells shift the polarization of macrophages toward a pro-tumoral state and augment their capability to accumulate lipid droplets when triggered with lipid species. In addition, autophagic flux resulted impaired in macrophages exposed to tumor cells, suggesting defective autophagy as a potential mechanism responsible for lipid accumulation. In the end, we observed that transcription factor EB (TFEB) is deregulated in tumor-conditioned macrophages, indicating a role of TFEB in promoting autophagy deficiency and lipid accumulation in TAMs.
Conclusions
Here we show that TAMs in melanoma accumulate lipids and acquire pro-tumorigenic and immunosuppressive features. Additionally, the inactivation of transcription factor EB promotes a defective autophagic machinery that could be relevant in lipid accumulation in TAMs. In this context, we believe that TFEB activation may prevent lipid accumulation thus potentially improving efficacy of current available immunotherapies and therefore representing a promising opportunity for cancer therapy.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Fondazione AIRC per la Ricerca sul Cancro.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
158P - Enhancing the communication of genomic results: Understanding patient and clinician perspectives
Presenter: Eleanor Johnston
Session: Cocktail & Poster Display session
Resources:
Abstract
159P - Precision medicine-based platform to guide the treatment of EML4-ALK fusion lung cancers and other NSCLC
Presenter: Nathan Merrill
Session: Cocktail & Poster Display session
Resources:
Abstract
160P - CICLADES-CE study: Genomic signatures detected in DNA from FFPE samples of patients with advanced or metastatic breast cancers treated with anti-aromatase and CDK4/6 inhibitors
Presenter: Margaux BETZ
Session: Cocktail & Poster Display session
Resources:
Abstract
161P - PDL1 expression and its relation to EML4-ALK gene variants in metastatic lung adenocarcinoma: A single-center real-world experience
Presenter: Santhosh Meedimale
Session: Cocktail & Poster Display session
Resources:
Abstract
163P - Impact of genomic sequencing data on treatment decisions in advanced breast cancer (ABC)
Presenter: Sviatoslav Chekhun
Session: Cocktail & Poster Display session
Resources:
Abstract
164P - Clinical utility of comprehensive molecular profiling tests for advanced gastrointestinal tumors
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract
165P - Evaluation of the mutational profile in patients with metastatic non-small cell lung carcinoma diagnosed in a tertiary hospital which was performed by NGS method
Presenter: Kankan Deka
Session: Cocktail & Poster Display session
Resources:
Abstract
166P - Targeted next-generation sequencing as reliable detection of genetic profile for cancer treatment to guide oncologists in Pakistan
Presenter: Zeeshan Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
167P - Molecular analysis of gastrointestinal stromal tumor (GIST): The experience of Regina Elena National Cancer Institute
Presenter: Andrea Torchia
Session: Cocktail & Poster Display session
Resources:
Abstract
168P - Usefulness of liquid biopsy in the management of patients with advanced or metastatic pancreatic cancer
Presenter: Jorge Iranzo Barreira
Session: Cocktail & Poster Display session
Resources:
Abstract